Large gap with delayed quotes
|
Last quote
08/15/2026
-
02:00:00
|
Bid
08/14/2026 -
21:59:59
|
Bid Volume |
Ask
08/14/2026 -
21:59:59
|
Ask Volume |
|---|---|---|---|---|
|
115.96
+6.36
(
+5.80% )
|
115.74
|
3,100 |
115.95
|
1,000 |
Analysis date: 14.08.2026
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 23.06.2026.
Interest
Strong
Strong
Three stars since 07.07.2026.
Earnings Rev Trend
0.10
0.10
Compared to seven weeks ago, the analysts have not significantly revised their earnings per share estimates (changes between +1% and -1% are considered neutral). But the last significant trend is positive since 07.07.2026 at a price of 95.76.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 23.06.2026.
4wk Rel Perf
11.28%
11.28%
The four-week dividend-adjusted overperformance versus SP500 is 11.28%.
Sensibility
High
High
The stock has been on the high-sensitivity level since 21.04.2026.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -2.26%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 4.77%.
Mkt Cap in $bn
6.49
6.49
With a market capitalization between $2 & $8bn, DIANTHUS THERAPEUTICS is considered a mid-cap stock.
G/PE Ratio
-0.95
-0.95
A negative ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) indicates that either the forecasted growth is decelerating (negative annualized growth estimate) or the financial analysts are expecting a loss (negative estimated PE).
LT P/E
-21.26
-21.26
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
-20.13%
-20.13%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
13
13
Over the last seven weeks, an average of 13 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
55
55
For 1% of index variation, the stock varies on average by 0.55%.
Correlation
0.05
0.05
Stock movements are totally independent of index variations.
Value at Risk
74.91
74.91
The value at risk is estimated at USD 74.91. The risk is therefore 64.60%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
21.04.2026
21.04.2026